SecBot SecBot
8-K ·Filed Jul 22, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001104659-26-085790
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine board resignation with no trading signal. Monitor future filings for appointment of a new director, which could indicate board composition changes but is unlikely to affect near-term stock price.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.68
T+0 close · Jul 22, 2026 · via day close
Latest settled
−28.00%
T+60 · $9.85
Vs SPY
−32.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 23 $13.68entry
  2. T+1 · 4mo ago −4.46%α −4.56% · $13.07
  3. T+5 · 4mo ago −3.58%α −4.06% · $13.19
  4. T+20 · 3mo ago +4.75%α +1.44% · $14.33
  5. T+60 · 5w ago −28.00%α −32.55% · $9.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Ian T. Clark resigned from the board of Corvus Pharmaceuticals, effective July 22, 2026, after over nine years of service. No reason was given beyond his notice of intention to resign, and no replacement has been named. This is a routine board-level departure with no immediate impact on operations or strategy.

Key Facts

  • Ian T. Clark delivered notice of resignation from the board on July 21, 2026, effective July 22, 2026.
  • Clark served on the board for over nine years.
  • No replacement director has been named in the filing.
  • The company thanked Clark for his contributions; no mention of disagreement or conflict.

Financial Impact

No material financial impact from a single director resignation.

Risk Factors

  • Loss of board expertise if Clark's departure leaves a gap in relevant experience, though no immediate risk.
  • Potential for additional board departures if internal issues exist, though none indicated.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-085790
Document: 0001104659-26-085790-index-headers.html0001104659-26-085790
Document: 0001104659-26-085790-index.html0001104659-26-085790
Document: 0001104659-26-085790.txt0001104659-26-085790

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Viewing Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026